The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2026

Filed:

Aug. 20, 2021
Applicants:

Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, CN;

Ascentage Pharma Group Corp Limited, Central, CN;

Inventors:

Yifan Zhai, Suzhou, CN;

Dajun Yang, Suzhou, CN;

Dong Fang, Suzhou, CN;

Saijie Zhu, Suzhou, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61P 13/12 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61P 13/12 (2018.01); A61P 37/06 (2018.01);
Abstract

Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.


Find Patent Forward Citations

Loading…